AR099999A1 - Inhibidores macrocíclicos de quinasas cdk9 con actividad antiproliferativa mejorada - Google Patents
Inhibidores macrocíclicos de quinasas cdk9 con actividad antiproliferativa mejoradaInfo
- Publication number
- AR099999A1 AR099999A1 ARP150101081A ARP150101081A AR099999A1 AR 099999 A1 AR099999 A1 AR 099999A1 AR P150101081 A ARP150101081 A AR P150101081A AR P150101081 A ARP150101081 A AR P150101081A AR 099999 A1 AR099999 A1 AR 099999A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- group
- acetylamino
- halo
- cycloalkyl
- Prior art date
Links
- 102100024457 Cyclin-dependent kinase 9 Human genes 0.000 title 1
- 101000980930 Homo sapiens Cyclin-dependent kinase 9 Proteins 0.000 title 1
- 230000001028 anti-proliverative effect Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 13
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 6
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 6
- 125000001072 heteroaryl group Chemical group 0.000 abstract 6
- 125000000623 heterocyclic group Chemical group 0.000 abstract 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 6
- 125000001424 substituent group Chemical group 0.000 abstract 6
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 5
- -1 acetylamino, N-methyl-N-acetylamino Chemical group 0.000 abstract 5
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 5
- 229910052736 halogen Inorganic materials 0.000 abstract 5
- 150000002367 halogens Chemical class 0.000 abstract 5
- 125000003282 alkyl amino group Chemical group 0.000 abstract 4
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 abstract 2
- 229910052801 chlorine Inorganic materials 0.000 abstract 2
- 125000001309 chloro group Chemical group Cl* 0.000 abstract 2
- 229910052731 fluorine Inorganic materials 0.000 abstract 2
- 125000001153 fluoro group Chemical group F* 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 125000006592 (C2-C3) alkenyl group Chemical group 0.000 abstract 1
- 125000006593 (C2-C3) alkynyl group Chemical group 0.000 abstract 1
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 abstract 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract 1
- 229910052794 bromium Inorganic materials 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
- C07C53/16—Halogenated acetic acids
- C07C53/18—Halogenated acetic acids containing fluorine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
Abstract
Reivindicación 1: Un compuesto caracterizado porque es de fórmula general (1) donde A representa un grupo bivalente seleccionado entre el grupo que consiste en -S-, -S(=O)-, -S(=O)₂-, -S(=O)(=NR⁵)-; L representa un grupo C₂₋₆-alquileno, donde dicho grupo está opcionalmente sustituido con (i) un sustituyente seleccionado entre hidroxi, C₂₋₃-alquenilo, C₂₋₃-alquinilo, C₃₋₄-cicloalquilo, hidroxi-C₁₋₃-alquilo, -(CH₂)NR⁶R⁷, y/o (ii) uno o dos o tres sustituyentes, idénticos o diferentes, seleccionados entre halógeno y C₁₋₃-alquilo, con la condición de que un grupo C₂-alquileno no está sustituido con un grupo hidroxi, o donde un átomo de carbono de dicho grupo C₂₋₆-alquileno forma un anillo de tres o cuatro miembros junto con un grupo bivalente al cual está unido, donde dicho grupo bivalente se selecciona entre -CH₂CH₂-, -CH₂CH₂CH₂-, -CH₂OCH₂-; X, Y representan CH o N con la condición de que uno de X e Y representa CH y uno de X e Y representa N; R¹ representa un grupo seleccionado entre C₁₋₆-alquilo, C₃₋₆-alquenilo, C₃₋₆-alquinilo, C₃₋₇ cicloalquilo, heterociclilo, fenilo, heteroarilo, fenil-C₁₋₃-alquilo y heteroaril-C₁₋₃-alquilo, donde dicho grupo está opcionalmente sustituido con uno o dos o tres sustituyentes, idénticos o diferentes, seleccionados entre el grupo que consiste en hidroxi, ciano, halógeno, C₁₋₆-alquilo, halo-C₁₋₃-alquilo, C₁₋₆-alcoxi, C₁₋₃-fluoroalcoxi, -NH₂, alquilamino, dialquilamino, acetilamino, N-metil-N-acetilamino, aminas cíclicas, -OP(=O)(OH)₂, -C(=O)OH, -C(=O)NH₂; R² representa un grupo seleccionado entre un átomo de hidrógeno, un átomo de flúor, un átomo de cloro, un átomo de bromo, ciano, C₁₋₃-alquilo, C₁₋₃-alcoxi, halo-C₁₋₃-alquilo, C₁₋₃-fluoroalcoxi; R³, R⁴ representan, en forma independiente entre sí, un grupo seleccionado entre un átomo de hidrógeno, un átomo de flúor, un átomo de cloro, un átomo de bromo, ciano, C₁₋₃-alquilo, C₁₋₃-alcoxi, halo-C₁₋₃-alquilo, C₁₋₃-fluoroalcoxi; R⁵ representa un grupo seleccionado entre un átomo de hidrógeno, ciano, -C(=O)R⁸, -C(=O)OR⁸, -S(=O)₂R⁸, -C(=O)NR⁶R⁷, C₁₋₆-alquilo, C₃₋₇-cicloalquilo, heterociclilo, fenilo, heteroarilo, donde dicho grupo C₁₋₆-alquilo, C₃₋₇-cicloalquilo, heterociclilo, fenilo o heteroarilo está opcionalmente sustituido con uno, dos o tres sustituyentes, idénticos o diferentes, seleccionados entre el grupo que consiste en halógeno, hidroxi, ciano, C₁₋₃-alquilo, C₁₋₃-alcoxi, -NH₂, alquilamino, dialquilamino, acetilamino, N-metil-N-acetilamino, aminas cíclicas, halo-C₁₋₃-alquilo, C₁₋₃-fluoroalcoxi; R⁶, R⁷ representan, en forma independiente entre sí, un grupo seleccionado entre un átomo de hidrógeno, C₁₋₆-alquilo, C₃₋₇-cicloalquilo, heterociclilo, fenilo, bencilo y heteroarilo, donde dicho grupo C₁₋₆-alquilo, C₃₋₇-cicloalquilo, heterociclilo, fenilo, bencilo o heteroarilo está opcionalmente sustituido con uno, dos o tres sustituyentes, idénticos o diferentes, seleccionados entre el grupo que consiste en halógeno, hidroxi, C₁₋₃-alquilo, C₁₋₃-alcoxi, -NH₂, alquilamino, dialquilamino, acetilamino, N-metil-N-acetilamino, aminas cíclicas, halo-C₁₋₃-alquilo, C₁₋₃-fluoroalcoxi, o R⁶ y R⁷, junto con el átomo de nitrógeno al que se unen, forman una amina cíclica; R⁸ representa un grupo seleccionado entre C₁₋₆-alquilo, halo-C₁₋₃-alquilo, C₃₋₇-cicloalquilo, heterociclilo, fenilo, bencilo y heteroarilo, donde dicho grupo está opcionalmente sustituido con uno, dos o tres sustituyentes, idénticos o diferentes, seleccionados entre el grupo que consiste en halógeno, hidroxi, C₁₋₃-alquilo, C₁₋₃-alcoxi, -NH₂, alquilamino, dialquilamino, acetilamino, N-metil-N-acetilamino, aminas cíclicas, halo-C₁₋₃-alquilo, C₁₋₃-fluoroalcoxi; enantiómero, diasterómero, sal, solvato o sal de solvato del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2014000392 | 2014-04-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR099999A1 true AR099999A1 (es) | 2016-08-31 |
Family
ID=52824234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150101081A AR099999A1 (es) | 2014-04-11 | 2015-04-10 | Inhibidores macrocíclicos de quinasas cdk9 con actividad antiproliferativa mejorada |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US9963464B2 (es) |
| EP (1) | EP3129387B1 (es) |
| JP (1) | JP6605493B2 (es) |
| KR (1) | KR102383938B1 (es) |
| CN (1) | CN106459084B (es) |
| AP (1) | AP2016009483A0 (es) |
| AR (1) | AR099999A1 (es) |
| AU (1) | AU2015243585B2 (es) |
| BR (1) | BR112016023554B1 (es) |
| CA (1) | CA2945237C (es) |
| CL (1) | CL2016002577A1 (es) |
| CR (1) | CR20160471A (es) |
| CU (1) | CU24399B1 (es) |
| DO (1) | DOP2016000278A (es) |
| EA (1) | EA032541B1 (es) |
| ES (1) | ES2743799T3 (es) |
| IL (1) | IL247966B (es) |
| MX (1) | MX376962B (es) |
| PE (1) | PE20161379A1 (es) |
| PH (1) | PH12016501968A1 (es) |
| SG (1) | SG11201608430RA (es) |
| SV (1) | SV2016005301A (es) |
| TN (1) | TN2016000435A1 (es) |
| TW (1) | TW201623312A (es) |
| UA (1) | UA119349C2 (es) |
| UY (1) | UY36072A (es) |
| WO (1) | WO2015155197A1 (es) |
| ZA (1) | ZA201607765B (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108290903B (zh) * | 2015-09-29 | 2021-09-03 | 拜耳医药股份有限公司 | 新的大环磺酰二亚胺化合物 |
| US10214542B2 (en) | 2015-10-08 | 2019-02-26 | Bayer Pharma Aktiengesellschaft | Modified macrocyclic compounds |
| EA036551B1 (ru) * | 2016-04-22 | 2020-11-23 | Астразенека Аб | Макроциклические ингибиторы mcl1 для лечения рака |
| RU2019111887A (ru) * | 2016-10-20 | 2020-11-20 | Пфайзер Инк. | Антипролиферативные средства для лечения лаг |
| ES2900199T3 (es) | 2017-03-28 | 2022-03-16 | Bayer Ag | Novedosos compuestos macrocíclicos inhibidores de PTEFB |
| EP3601236A1 (en) | 2017-03-28 | 2020-02-05 | Bayer Aktiengesellschaft | Novel ptefb inhibiting macrocyclic compounds |
| CN109251212A (zh) * | 2017-07-14 | 2019-01-22 | 上海长森药业有限公司 | 内环硫醚酰胺-芳基酰胺类化合物及其治疗乙型肝炎的用途 |
| CN111434665B (zh) * | 2019-01-11 | 2023-03-10 | 上海长森药业有限公司 | 内环硫脒酰胺-芳基酰胺类化合物及其治疗乙型肝炎的用途 |
| CN112321604A (zh) * | 2019-08-05 | 2021-02-05 | 华东理工大学 | 大环类jak2抑制剂及其应用 |
| WO2023057812A1 (en) | 2021-10-04 | 2023-04-13 | Vincerx Pharma Gmbh | Compounds, pharmaceutical compositions, and methods for the treatment, prevention, or management of hyperproliferative disorder |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ304059B6 (cs) | 2000-12-21 | 2013-09-11 | Glaxo Group Limited | Deriváty pyrimidinu a farmaceutický prostredek |
| DE10239042A1 (de) * | 2002-08-21 | 2004-03-04 | Schering Ag | Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel |
| DE10349423A1 (de) | 2003-10-16 | 2005-06-16 | Schering Ag | Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
| BRPI0517426A (pt) | 2004-12-17 | 2008-10-07 | Astrazeneca Ab | composto, processo para preparar o mesmo, composição farmacêutica, uso de um composto, e, métodos para produzir um efeito anti-proliferação celular, para produzir um efeito inibitório de cdk2, e para tratar uma doença em um animal de sangue quente |
| DE102006042143A1 (de) | 2006-09-08 | 2008-03-27 | Bayer Healthcare Aktiengesellschaft | Neue substituierte Bipyridin-Derivate und ihre Verwendung |
| WO2008060248A1 (en) | 2006-11-15 | 2008-05-22 | S*Bio Pte Ltd. | Indole sustituted pyrimidines and use thereof in the treatment of cancer |
| MX2009006535A (es) | 2006-12-22 | 2009-06-26 | Novartis Ag | Derivados de indol-4-il-pirimidinil-2-il-amina y su uso como inhibidores de cinasa dependiente de ciclina. |
| WO2008079933A2 (en) | 2006-12-22 | 2008-07-03 | Novartis Ag | Heteroaryl-heteroaryl compounds as cdk inhibitors for the treatment of cancer, inflammation and viral infections |
| WO2008129071A1 (en) | 2007-04-24 | 2008-10-30 | Ingenium Pharmaceuticals Gmbh | Inhibitors of protein kinases |
| EP2137166B1 (en) | 2007-04-24 | 2012-05-30 | Ingenium Pharmaceuticals GmbH | 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases |
| ES2539518T3 (es) | 2007-04-24 | 2015-07-01 | Astrazeneca Ab | Inhibidores de proteínas quinasas |
| WO2008132138A1 (en) | 2007-04-25 | 2008-11-06 | Ingenium Pharmaceuticals Gmbh | Derivatives of 4,6-disubstituted aminopyrimidines |
| WO2009029998A1 (en) | 2007-09-06 | 2009-03-12 | Cytopia Research Pty Ltd | Retrometabolic compounds |
| GB0805477D0 (en) | 2008-03-26 | 2008-04-30 | Univ Nottingham | Pyrimidines triazines and their use as pharmaceutical agents |
| US8415381B2 (en) | 2009-07-30 | 2013-04-09 | Novartis Ag | Heteroaryl compounds and their uses |
| BR112012024017B1 (pt) | 2010-03-22 | 2021-12-07 | Lead Discovery Center Gmbh | Compostos derivados de triazina dissubstituída farmaceuticamente ativos, composição farmacêutica, método para a síntese destes e uso dos mesmos |
| CN103562184B (zh) | 2011-03-02 | 2016-04-27 | 利德探索中心有限公司 | 药学活性的二取代的吡啶衍生物 |
| EP2527332A1 (en) | 2011-05-24 | 2012-11-28 | Bayer Intellectual Property GmbH | 4-Aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group as CDK9 inhibitors |
| ES2587284T3 (es) * | 2011-09-16 | 2016-10-21 | Bayer Intellectual Property Gmbh | 5-Fluoro-pirimidinas 2,4-disustituidas como inhibidores selectivos de CDK9 |
| WO2013037894A1 (en) | 2011-09-16 | 2013-03-21 | Bayer Intellectual Property Gmbh | Disubstituted 5-fluoro pyrimidine derivatives containing a sulfoximine group |
| ES2597232T3 (es) | 2012-10-18 | 2017-01-17 | Bayer Pharma Aktiengesellschaft | 4-(orto)-fluorofenil-5-fluoropirimidin-2-il aminas que contienen un grupo sulfona |
| HUE032868T2 (en) | 2012-11-15 | 2017-11-28 | Bayer Pharma AG | 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfoximine group |
| JP6300818B2 (ja) | 2012-11-15 | 2018-03-28 | バイエル ファーマ アクチエンゲゼルシャフト | スルホキシイミン基を含有する４−（オルト）−フルオロフェニル−５−フルオロピリミジン−２−イルアミン |
| JP6371385B2 (ja) | 2013-07-04 | 2018-08-08 | バイエル ファーマ アクチエンゲゼルシャフト | スルホキシイミン置換５−フルオロ−ｎ−（ピリジン−２−イル）ピリジン−２−アミン誘導体およびそのｃｄｋ９キナーゼ阻害薬としての使用 |
| EP3116869A1 (en) | 2014-03-13 | 2017-01-18 | Bayer Pharma Aktiengesellschaft | 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group |
-
2015
- 2015-04-08 CU CU2016000152A patent/CU24399B1/es unknown
- 2015-04-08 CN CN201580030721.XA patent/CN106459084B/zh not_active Expired - Fee Related
- 2015-04-08 AU AU2015243585A patent/AU2015243585B2/en not_active Ceased
- 2015-04-08 ES ES15715715T patent/ES2743799T3/es active Active
- 2015-04-08 EA EA201692034A patent/EA032541B1/ru not_active IP Right Cessation
- 2015-04-08 CA CA2945237A patent/CA2945237C/en active Active
- 2015-04-08 PE PE2016001962A patent/PE20161379A1/es unknown
- 2015-04-08 TN TN2016000435A patent/TN2016000435A1/en unknown
- 2015-04-08 AP AP2016009483A patent/AP2016009483A0/en unknown
- 2015-04-08 WO PCT/EP2015/057546 patent/WO2015155197A1/en not_active Ceased
- 2015-04-08 MX MX2016013362A patent/MX376962B/es active IP Right Grant
- 2015-04-08 JP JP2016561318A patent/JP6605493B2/ja not_active Expired - Fee Related
- 2015-04-08 US US15/303,212 patent/US9963464B2/en active Active
- 2015-04-08 BR BR112016023554-1A patent/BR112016023554B1/pt not_active IP Right Cessation
- 2015-04-08 CR CR20160471A patent/CR20160471A/es unknown
- 2015-04-08 EP EP15715715.7A patent/EP3129387B1/en active Active
- 2015-04-08 KR KR1020167031177A patent/KR102383938B1/ko not_active Expired - Fee Related
- 2015-04-08 SG SG11201608430RA patent/SG11201608430RA/en unknown
- 2015-04-09 UY UY0001036072A patent/UY36072A/es not_active Application Discontinuation
- 2015-04-10 TW TW104111701A patent/TW201623312A/zh unknown
- 2015-04-10 AR ARP150101081A patent/AR099999A1/es unknown
- 2015-08-04 UA UAA201611295A patent/UA119349C2/uk unknown
-
2016
- 2016-09-22 IL IL247966A patent/IL247966B/en active IP Right Grant
- 2016-10-04 PH PH12016501968A patent/PH12016501968A1/en unknown
- 2016-10-11 SV SV2016005301A patent/SV2016005301A/es unknown
- 2016-10-11 CL CL2016002577A patent/CL2016002577A1/es unknown
- 2016-10-11 DO DO2016000278A patent/DOP2016000278A/es unknown
- 2016-11-10 ZA ZA2016/07765A patent/ZA201607765B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR099999A1 (es) | Inhibidores macrocíclicos de quinasas cdk9 con actividad antiproliferativa mejorada | |
| AR099177A1 (es) | Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1 | |
| AR099995A1 (es) | Piridilamidinas fungicidas | |
| CO2019005165A2 (es) | Compuesto de piridona como inhibidor de c-met | |
| AR110405A1 (es) | Compuestos | |
| AR099400A1 (es) | Compuesto heterocíclico fusionado | |
| AR100975A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR103990A1 (es) | Ureas cíclicas como inhibidoras de rock | |
| AR102177A1 (es) | Compuestos de heteroarilo como inhibidores de btk y usos de los mismos | |
| AR098136A1 (es) | Compuestos de heteroarilo como inhibidores de btk y usos de los mismos | |
| AR101367A1 (es) | Pirimidinonas como inhibidores del factor xia | |
| AR103561A1 (es) | Fenilpiridinas herbicidas | |
| AR095885A1 (es) | Compuestos derivados de arilpirrolopiridina como inhibidores de lrrk2 | |
| AR106604A1 (es) | Compuestos de criptoficina y productos conjugados, su preparación y su uso terapéutico | |
| AR100315A1 (es) | Compuestos de piridina sustituida que tienen acción herbicida | |
| AR106297A1 (es) | Compuestos macrocíclicos modificados como inhibidores selectivos de la quinasa cdk9 | |
| AR110088A1 (es) | Inhibidores de magl | |
| AR102256A1 (es) | Derivados biaromáticos básicos antibacterianos con sustitución de aminoalcoxi | |
| AR099789A1 (es) | Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina | |
| AR112086A1 (es) | Compuestos heteroaromáticos como inhibidores de vanina | |
| AR090572A1 (es) | Derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos | |
| AR093503A1 (es) | Derivados de n-(piridin-2-il)pirimidin-4-amina que contienen un grupo sulfoximina | |
| AR109776A1 (es) | Compuestos de p2x₃ y/o p2x₂/₃ y métodos | |
| AR109296A1 (es) | Derivados de oxadiazolopiridina para el uso como inhibidores de ghrelin o-aciltransferasa (goat) | |
| AR106185A1 (es) | Compuestos macrocíclicos de sulfondiimina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |